Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal

Implication de p38 et p53 dans le mécanisme d’action du cetuximab dans le cancer colorectal

Le cetuximab est une thérapie ciblée dirigée contre le récepteur du facteur de croissance épidermique (EGFR) utilisée dans le cancer colorectal (CCR) en combinaison avec des chimiothérapies (5-FU, irinotécan et oxaliplatine). Sa fixation inhibe les voies de signalisation en aval du récepteur conduis...

Full description

Bibliographic Details
Main Author:	Marzi, Laetitia
Other Authors:	Montpellier 1
Language:	fr
Published:	2014
Subjects:	Cancer colorectal Cetuximab P38mapk P53 Échec thérapeutique Inhibiteurs EGFR Colorectal cancer Therapies EGFR inhibitors 616
Online Access:	http://www.theses.fr/2014MON13525/document

Similar Items

Transfert des gènes p53 et pten par vectorisation non virale : effet pro-apoptotique et potentialisation de la réponse cellulaire au cétuximab
by: Bouali, Sanae
Published: (2008)

Étude des mécanismes de résistance à l’Irinotécan dans le cancer colorectal : implication de la MAPK p38
by: Paillas, Salomé
Published: (2011)

p38β and Cancer: The Beginning of the Road
by: Olga Roche, et al.
Published: (2020-10-01)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
by: Dahan Laetitia, et al.
Published: (2011-11-01)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01)

Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway
by: Chen L, et al.
Published: (2018-12-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

The Increase of ROS Caused by the Interference of DEHP with JNK/p38/p53 Pathway as the Reason for Hepatotoxicity
by: Yuanyuan Huang, et al.
Published: (2019-01-01)

Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer
by: Lorenzo Stramucci, et al.
Published: (2019-12-01)

Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer
by: Lorenzo Stramucci, et al.
Published: (2018-05-01)

Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway
by: Cheng Wang, et al.
Published: (2021-01-01)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
by: Ines De Pauw, et al.
Published: (2019-01-01)

Etude de l’effet sur la P‐glycoprotéine (ABCB1) de deux médicaments dirigés contre le récepteur de facteur de croissance épithélial (EGFR), le cétuximab et le lapatinib et conséquence sur la pharmacocinétique et l’efficacité anti‐tumorale de médicaments substrats de ABCB1
by: Chu, Céline
Published: (2013)

A Special View of What Was Almost Forgotten: p38δ MAPK
by: Débora Bublitz Anton, et al.
Published: (2021-04-01)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

Inhibition isoforme spécifique des fonctions de la MAPK p38α par des fragments d’anticorps
by: Renaud, Emilie
Published: (2018)

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies
by: Pelaia C, et al.
Published: (2021-03-01)

The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments
by: Angelina Pranteda, et al.
Published: (2020-04-01)

Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer
by: Hongming Zhang, et al.
Published: (2019-07-01)

B Cell Development and T-Dependent Antibody Response Are Regulated by p38γ and p38δ
by: Laura Barrio, et al.
Published: (2020-03-01)

Curcumol Inhibits Growth and Induces Apoptosis of Colorectal Cancer LoVo Cell Line via IGF-1R and p38 MAPK Pathway
by: Juan Wang, et al.
Published: (2015-08-01)

Protective effect of Anwulignan against D-galactose-induced hepatic injury through activating p38 MAPK–Nrf2–HO-1 pathway in mice
by: Gao J, et al.
Published: (2018-10-01)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
by: Dalyong Kim, et al.
Published: (2017-11-01)

Immunohitochemical expression of p53 in human colocrectal carcinoma
by: Sazan abdulwahab Mirza, et al.
Published: (2016-10-01)

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
by: Na Song, et al.
Published: (2014-04-01)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
by: Scartozzi Mario, et al.
Published: (2012-04-01)

Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway
by: Ren-hong Huang, et al.
Published: (2017-04-01)

p38MAPK plays a pivotal role in the development of acute respiratory distress syndrome
by: Ying Feng, et al.

Avaluació preclínica de l'efecte antitumoral de cetuximab sobre la malaltia microscòpica residual post-radioteràpia
by: Pueyo Castells, Gemma
Published: (2010)

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
by: Nemecek R, et al.
Published: (2016-07-01)

Comprometimento funcional de células dendríticas derivadas de monócitos de pacientes com câncer: envolvimento das vias de sinalização p38 e ERK1/2 (p44/p42) MAPK.
by: Bruna Zelante Barbosa
Published: (2017)

Comprometimento funcional de células dendríticas derivadas de monócitos de pacientes com câncer: envolvimento das vias de sinalização p38 e ERK1/2 (p44/p42) MAPK.
by: Barbosa, Bruna Zelante
Published: (2017)

Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness
by: Charles S. Goldsmith, et al.
Published: (2018-01-01)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
by: Florian Huemer, et al.
Published: (2018-01-01)

The Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 Status
by: Sefer Elezkurtaj, et al.
Published: (2011-03-01)

Organizing pneumonia secondary to cetuximab in a patient with colorectal cancer
by: Abdulaziz AlGhulayqah, et al.
Published: (2019-09-01)

The roles of Monoamine Oxidase-A and p38(MAPK) in breast cancer
Published: (2013)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells
by: Cui J, et al.
Published: (2019-11-01)

Flavopereirine Inhibits Autophagy via the AKT/p38 MAPK Signaling Pathway in MDA-MB-231 Cells
by: Ming-Shan Chen, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_dpeobnshnamqpo50qs9ldao9vk